244 related articles for article (PubMed ID: 27431016)
1. Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.
Saleh LM; Wang W; Herman SE; Saba NS; Anastas V; Barber E; Corrigan-Cummins M; Farooqui M; Sun C; Sarasua SM; Zhao Z; Abousamra NK; Elbaz O; Abdelghaffar HA; Wiestner A; Calvo KR
Leukemia; 2017 Feb; 31(2):340-349. PubMed ID: 27431016
[TBL] [Abstract][Full Text] [Related]
2. Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodes.
Palma M; Krstic A; Peña Perez L; Berglöf A; Meinke S; Wang Q; Blomberg KEM; Kamali-Moghaddam M; Shen Q; Jaremko G; Lundin J; De Paepe A; Höglund P; Kimby E; Österborg A; Månsson R; Smith CIE
Br J Haematol; 2018 Oct; 183(2):212-224. PubMed ID: 30125946
[TBL] [Abstract][Full Text] [Related]
3. TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib.
Dadashian EL; McAuley EM; Liu D; Shaffer AL; Young RM; Iyer JR; Kruhlak MJ; Staudt LM; Wiestner A; Herman SEM
Cancer Res; 2019 Jan; 79(2):360-371. PubMed ID: 30498085
[TBL] [Abstract][Full Text] [Related]
4. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation.
Yeomans A; Thirdborough SM; Valle-Argos B; Linley A; Krysov S; Hidalgo MS; Leonard E; Ishfaq M; Wagner SD; Willis AE; Steele AJ; Stevenson FK; Forconi F; Coldwell MJ; Packham G
Blood; 2016 Jan; 127(4):449-57. PubMed ID: 26491071
[TBL] [Abstract][Full Text] [Related]
5. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
6. ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
Kwok M; Davies N; Agathanggelou A; Smith E; Oldreive C; Petermann E; Stewart G; Brown J; Lau A; Pratt G; Parry H; Taylor M; Moss P; Hillmen P; Stankovic T
Blood; 2016 Feb; 127(5):582-95. PubMed ID: 26563132
[TBL] [Abstract][Full Text] [Related]
7. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
8. The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia.
Guinn D; Lehman A; Fabian C; Yu L; Maddocks K; Andritsos LA; Jones JA; Flynn JM; Jaglowski SM; Woyach JA; Byrd JC; Johnson AJ
Cancer Med; 2017 Apr; 6(4):778-787. PubMed ID: 28299881
[TBL] [Abstract][Full Text] [Related]
9. miR-34a and miR-29b as indicators for prognosis of treatment-free survival of chronic lymphocytic leukemia patients in Chinese Uygur and Han populations.
Li Y; Mao M; Liu H; Wang X; Kou Z; Nie Y; Wang Y; Wang Z; Huang Q; Lang T; Gu Z; An L; Zhang X; Fu L
Mol Cell Probes; 2019 Oct; 47():101436. PubMed ID: 31425738
[TBL] [Abstract][Full Text] [Related]
10. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells.
Li S; Moffett HF; Lu J; Werner L; Zhang H; Ritz J; Neuberg D; Wucherpfennig KW; Brown JR; Novina CD
PLoS One; 2011 Mar; 6(3):e16956. PubMed ID: 21408091
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia.
Morande PE; Sivina M; Uriepero A; Seija N; Berca C; Fresia P; Landoni AI; Di Noia JM; Burger JA; Oppezzo P
Blood; 2019 May; 133(19):2056-2068. PubMed ID: 30814061
[TBL] [Abstract][Full Text] [Related]
13. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765).
Burger JA; Buggy JJ
Leuk Lymphoma; 2013 Nov; 54(11):2385-91. PubMed ID: 23425038
[TBL] [Abstract][Full Text] [Related]
14. MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia.
Saba NS; Wong DH; Tanios G; Iyer JR; Lobelle-Rich P; Dadashian EL; Liu D; Fontan L; Flemington EK; Nichols CM; Underbayev C; Safah H; Melnick A; Wiestner A; Herman SEM
Cancer Res; 2017 Dec; 77(24):7038-7048. PubMed ID: 28993409
[TBL] [Abstract][Full Text] [Related]
15. Silencing of HDAC6 as a therapeutic target in chronic lymphocytic leukemia.
Maharaj K; Powers JJ; Achille A; Deng S; Fonseca R; Pabon-Saldana M; Quayle SN; Jones SS; Villagra A; Sotomayor EM; Sahakian E; Pinilla-Ibarz J
Blood Adv; 2018 Nov; 2(21):3012-3024. PubMed ID: 30425065
[TBL] [Abstract][Full Text] [Related]
16. NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib.
Wolf C; Garding A; Filarsky K; Bahlo J; Robrecht S; Becker N; Zucknick M; Rouhi A; Weigel A; Claus R; Weichenhan D; Eichhorst B; Fischer K; Hallek M; Kuchenbauer F; Plass C; Döhner H; Stilgenbauer S; Lichter P; Mertens D
Int J Cancer; 2018 Jan; 142(2):322-333. PubMed ID: 28921505
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL.
Herman SE; Mustafa RZ; Gyamfi JA; Pittaluga S; Chang S; Chang B; Farooqui M; Wiestner A
Blood; 2014 May; 123(21):3286-95. PubMed ID: 24659631
[TBL] [Abstract][Full Text] [Related]
18. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.
Ryan CE; Sahaf B; Logan AC; O'Brien S; Byrd JC; Hillmen P; Brown JR; Dyer MJ; Mato AR; Keating MJ; Jaglowski S; Clow F; Rezvani AR; Styles L; Coutre SE; Miklos DB
Blood; 2016 Dec; 128(25):2899-2908. PubMed ID: 27802969
[TBL] [Abstract][Full Text] [Related]
19. Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.
Skarzynski M; Niemann CU; Lee YS; Martyr S; Maric I; Salem D; Stetler-Stevenson M; Marti GE; Calvo KR; Yuan C; Valdez J; Soto S; Farooqui MZ; Herman SE; Wiestner A
Clin Cancer Res; 2016 Jan; 22(1):86-95. PubMed ID: 26283682
[TBL] [Abstract][Full Text] [Related]
20. Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia.
Tissino E; Benedetti D; Herman SEM; Ten Hacken E; Ahn IE; Chaffee KG; Rossi FM; Dal Bo M; Bulian P; Bomben R; Bayer E; Härzschel A; Gutjahr JC; Postorino M; Santinelli E; Ayed A; Zaja F; Chiarenza A; Pozzato G; Chigaev A; Sklar LA; Burger JA; Ferrajoli A; Shanafelt TD; Wiestner A; Del Poeta G; Hartmann TN; Gattei V; Zucchetto A
J Exp Med; 2018 Feb; 215(2):681-697. PubMed ID: 29301866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
